About Ardelyx
Translating Scientific Breakthroughs into Promise for Patients
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Waltham, MA
- Founded
- 2007
- Company type
- Public Company
- Company profile name
- Ardelyx, Inc.
Ardelyx is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). The company’s pipeline includes the Phase 3 development of IBSRELA for chronic idiopathic constipation (CIC) and RDX10531, a next-generation NHE3 inhibitor with potential application across multiple therapeutic areas. Ardelyx works with its partners to develop and commercialize its products outside of the United States.
Community Guidelines: https://rb.gy/07ltg3
Company locations
400 Fifth Avenue, 210, Waltham, MA 02451, US
7999 Gateway Blvd, Suite 110, Newark, California 94560, US
260 E Highland Ave, Milwaukee, Wisconsin 53202, US
Locations listed on the company profile. These may include offices outside the United States, and not every location is hiring.
Business areas
- Health Care
- Biotechnology
- Medical
On LinkedIn
- Followers
- 27,864
- People linked to this company
- 531
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Funding raised
607,675,321 USD
Total reported by Crunchbase, in US dollars. This is funding raised, not company revenue or valuation.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.